Study results concerning remdesivir benefits in COVID-19
Remdesivir is the only drug other than dexamethasone shown to benefit those infected with COVID-19 in a large, randomized trial. It shortened the amount of time patients needed to spend in the hospital, but it did not have a statistically significant benefit in preventing deaths. It is the only drug that has gained emergency use authorization from the US FDA.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Early randomized trials are unable to provide evidence for reducing time to clinical improvement, clearance of virus, or mortality amongst those given Remdesivir as COVID-19 intervention
Adverse health effects amongst those given Remdesivir as COVID-19 intervention
Study results concerning remdesivir benefits in COVID-19
Availability of remdesivir
Clinical trials of Remdesivir around the world
Intracellular processing of Remdesivir
Global Production of Remdesivir